CD-Venture

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

Wellth is a digital health company based in New York that operates a mobile application aimed at improving treatment adherence among individuals with chronic conditions. The platform leverages principles from behavioral economics to address the unique challenges faced by these patients in establishing healthy habits and managing their diseases. By offering targeted incentive plans, reminders, and valuable information, Wellth encourages consumers to take proactive steps toward their health, thus reducing overall healthcare costs. The application's design fosters motivation and behavior change, as it is supported by evidence from randomized controlled trials demonstrating its effectiveness. Wellth's approach has been validated by health plans and providers, resulting in improved medication adherence, reduced hospital readmissions, and better health outcomes for users.

Wellth is a digital health company based in New York that operates a mobile application aimed at improving treatment adherence among individuals with chronic conditions. The platform leverages principles from behavioral economics to address the unique challenges faced by these patients in establishing healthy habits and managing their diseases. By offering targeted incentive plans, reminders, and valuable information, Wellth encourages consumers to take proactive steps toward their health, thus reducing overall healthcare costs. The application's design fosters motivation and behavior change, as it is supported by evidence from randomized controlled trials demonstrating its effectiveness. Wellth's approach has been validated by health plans and providers, resulting in improved medication adherence, reduced hospital readmissions, and better health outcomes for users.

TriOptoTec GmbH is a company based in Regensburg, Germany, that specializes in hygiene solutions for hospitals and nursing homes. Founded in 2010, it develops and markets innovative products aimed at improving sanitation and infection control. The company offers a range of solutions, including DyCoat, a permanent antimicrobial paint, a universal coating system, and daily cleaning wipes. Additionally, TriOptoTec is involved in the development of light-active dyes designed to effectively combat germs and bacteria. Through its brand "dyphox," the company focuses on photodynamic disinfection and decontamination, providing essential products and services that enhance hygiene in healthcare settings.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

Wellth is a digital health company based in New York that operates a mobile application aimed at improving treatment adherence among individuals with chronic conditions. The platform leverages principles from behavioral economics to address the unique challenges faced by these patients in establishing healthy habits and managing their diseases. By offering targeted incentive plans, reminders, and valuable information, Wellth encourages consumers to take proactive steps toward their health, thus reducing overall healthcare costs. The application's design fosters motivation and behavior change, as it is supported by evidence from randomized controlled trials demonstrating its effectiveness. Wellth's approach has been validated by health plans and providers, resulting in improved medication adherence, reduced hospital readmissions, and better health outcomes for users.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

Leon Nanodrugs is a specialized product development company focused on enhancing existing drug formulations through advanced nanotechnology. The company develops a pipeline of improved drug products aimed at increasing the bioavailability of poorly water-soluble medicines. Utilizing its proprietary MJR® Technology platform, Leon Nanodrugs creates both polymeric and crystalline nanoparticles, which provide significant differentiation and added benefits for patients. The company also offers services that support pre-clinical and clinical-stage formulations for clients’ new chemical entities or established branded drugs, facilitating access to next-generation nano-formulated therapies that aim to improve patient outcomes.

VENITI is the first medical device company developing a suite of innovative technology and solutions that will provide comprehensive treatment across the venous disease continuum. Venous disease refers to all conditions related to or caused by veins that become diseased or abnormal. This encompasses a broad set of maladies. The venous disease cycle begins when vein walls become weak or damaged, or the valves are stretched or injured, and can no longer prevent reflux (backward flow of blood). Once the veins lose their ability to convey blood without reflux, the progressive venous disease cycle has begun. This is commonly referred to as chronic venous insufficiency, or CVI. The blood will begin to back up into the peripheral veins, causing venous hypertension, potential thrombosis (clotting), and leading to even more damage of the vein walls and valves. This in turn leads to more reflux. The VENITI team of experts in science, technology and business are currently developing the VENITI VICI VENOUS STENT® System. Through this, and other, innovative technology, VENITI will achieve results that sets it apart in addressing the challenges specific to the venous system and venous disease.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Flex Pharma, Inc. is a biotechnology company focused on developing and commercializing innovative treatments for muscle cramps, spasms, and spasticity related to neurological conditions and exercise-associated muscle cramps. Founded in 2014 and headquartered in Boston, Massachusetts, the company operates in two segments: Consumer Operations and Drug Development. Its lead drug candidate, FLX-787, is a dual transient receptor potential V1/A1 ion channel activator that has completed an exploratory Phase II clinical trial in Australia for patients with multiple sclerosis. Additionally, Flex Pharma offers HOTSHOT, a consumer beverage designed to prevent and treat exercise-associated muscle cramps, which is marketed through its direct-to-consumer website and third-party platforms. In 2019, Flex Pharma was acquired by Salarius Pharmaceuticals, marking a significant shift in its operational structure.

Exosome Diagnostics, Inc. is a biotechnology company focused on developing biofluid-based molecular diagnostic tests to enhance personalized precision healthcare. The company utilizes its proprietary exosome technology to analyze nucleic acids from exosomes found in various biofluids, including blood, urine, and cerebrospinal fluid. This approach allows for high sensitivity and specificity in detecting rare gene transcripts associated with cancers and other serious diseases, enabling non-invasive diagnostic processes that reduce the need for tissue biopsies. One of its key products is the MedOncAlyzer 170, a liquid biopsy pan-cancer panel that assesses exosomal RNA and circulating tumor DNA in a single assay, identifying clinically relevant mutations across multiple cancer types. Additionally, Exosome Diagnostics collaborates with pharmaceutical companies to enhance research and development efforts, from biomarker discovery to the creation of companion diagnostics. Founded in 2008 and based in Cambridge, Massachusetts, the company was previously known as Exosome Theranostics, Inc. and became a subsidiary of Bio-Techne Corporation in 2018.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Stocard GmbH is a technology company that specializes in developing rewards applications for mobile devices, including iPhone and Android. Founded in 2011 and headquartered in Mannheim, Germany, with additional offices in several European cities and Australia, Stocard offers the StocardApp, which allows users to store and manage their loyalty cards, access coupons, and browse catalogs from various retailers. The app functions as a mobile wallet, streamlining the shopping experience for over 50 million users worldwide by facilitating several billion transactions at the point of sale. Stocard aims to enhance user engagement and simplify rewards collection while also providing access to financial services on its platform.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Curetis AG is a Germany-based company that specializes in developing molecular diagnostics solutions for infectious diseases. Founded in 2015 and now operating as a subsidiary of OpGen, Inc., Curetis focuses on the detection of pathogens and antibiotic resistance markers. The company offers a rapid diagnostic platform that enables multiparameter testing of various analytes in a single run, providing comprehensive panels for detecting a wide range of pathogens and resistance genes. This innovative approach aims to improve patient outcomes by delivering early, actionable information to healthcare providers, particularly in the context of severe bacterial infections. Curetis's technology not only addresses current healthcare challenges but also presents opportunities for future expansions into other clinical applications beyond infectious diseases.

Phenex Pharmaceuticals AG is a privately held drug discovery and development company based in Ludwigshafen, Germany, with additional facilities in Heidelberg. Founded in 2002, the company specializes in small-molecule drug discovery, focusing on liver diseases, intestinal diseases, and cancer. Its research includes developing retinoid-acid receptor-related orphan receptor gamma t (RORγt) inverse agonists for autoimmune diseases and farnesoid X receptor (FXR) agonists for non-alcoholic steatohepatitis. Phenex aims to identify novel molecular mechanisms and develop innovative therapeutics, having already translated two such mechanisms into proprietary small molecules.